CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
CRISPR Therapeutics (CRSP) PT Lowered to $59 at Barclays
August 6, 2024 3:02 AM EDTBarclays analyst Gena Wang lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $59.00 (from $67.00) while maintaining a Equalweight rating.... More
CRISPR Therapeutics (CRSP) Misses Q2 EPS by 6c
August 5, 2024 4:04 PM EDTCRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($1.49), $0.06 worse than the analyst estimate of ($1.43).
For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.
... MoreRodman & Renshaw Starts CRISPR Therapeutics (CRSP) at Buy
August 2, 2024 6:44 AM EDTRodman & Renshaw analyst Tony Butler initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $90.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $54.85 yesterday.
... More